BCLI vs. NBRV, VIRI, ITRM, SCYX, DTIL, ELEV, VTVT, ESLA, RAPT, and CLNN
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Nabriva Therapeutics (NBRV), Virios Therapeutics (VIRI), Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Precision BioSciences (DTIL), Elevation Oncology (ELEV), vTv Therapeutics (VTVT), Estrella Immunopharma (ESLA), RAPT Therapeutics (RAPT), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry.
Brainstorm Cell Therapeutics vs.
Nabriva Therapeutics (NASDAQ:NBRV) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Nabriva Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by company insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.
Brainstorm Cell Therapeutics has a consensus price target of $30.00, indicating a potential upside of 1,208.33%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Nabriva Therapeutics.
Nabriva Therapeutics received 102 more outperform votes than Brainstorm Cell Therapeutics when rated by MarketBeat users. However, 61.01% of users gave Brainstorm Cell Therapeutics an outperform vote while only 55.67% of users gave Nabriva Therapeutics an outperform vote.
Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.
In the previous week, Nabriva Therapeutics and Nabriva Therapeutics both had 1 articles in the media. Brainstorm Cell Therapeutics' average media sentiment score of 1.00 beat Nabriva Therapeutics' score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media.
Summary
Brainstorm Cell Therapeutics beats Nabriva Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCLI) was last updated on 1/21/2025 by MarketBeat.com Staff
Free BCLI Stock Alerts